Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program.

INTRODUCTION: Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its commercial availability for SA patients with no other available therapeutic options. We aimed to assess the real-world effectiveness of dupilumab in patients with SA and unmet needs.
METHODS: We performed a multicentre retrospective study, including SA patients admitted to the NPP treated with dupilumab for 12 months. Data on the number of exacerbations, Asthma Control Test (ACT), pre-bronchodilator FEV1%, oral corticosteroids (OCSs) use, FeNO and eosinophils count in peripheral blood were recorded at baseline and after 3, 6, and 12 months.
RESULTS: We included 18 SA patients (mean age 53.3±12.4 years, 66.7% female). Eleven (61.1%) were OCSs dependent. Five patients (27.8%) received previous anti-IgE and/or anti-IL-5 agents. A significant improvement in ACT score (from 15.7±5.1 to 18.8±4.8, p=0.023), OCSs intake [10 (5-25) mg/day to 0 (0-5) mg/day, p=0.0333] and FeNO [from 25 (20-80) ppb to 21 (10.9-55.3) ppb, p=0.0190] was already detected after 3 months of treatment. After 12 months, a statistically significant decrease in the number of exacerbations from 2 (0-3) to 0 (0-1) (p<0.0068) and increase in FEV1% from 73.5±19.5% to 87.1±19.2% (p=0.0407) and ACT to a mean value of 22.4±1.7 (p<0.0001) and the interruption of OCSs in all the patients (p<0.0001) was observed. A transient increase in the eosinophil count was observed in five patients (above 1000 cells/μL in 2 cases) after 3 months, without any clinical effect.
CONCLUSION: Dupilumab improved all the explored clinical outcomes after 12 months, and the transient hypereosinophilia did not modify treatment response. These real-world data confirm the results reported in randomized controlled trials and provide an important opportunity to characterize the clinical impact of the treatment in a non-trial setting. Further real-world studies with a larger cohort of patients are needed to confirm these findings.

Introduction

Asthma is a largely diffuse chronic respiratory disorder characterized by airway inflammation, hyperresponsiveness of bronchi and often reversible bronchial obstruction. As a consequence, it may have a relevant impact on daily symptoms and can be a trigger for unpredictable acute exacerbations.

Although most asthma patients are well controlled with current standard therapies, about 3.7–10% of them are affected by severe asthma (SA).1,2 SA is defined as an uncontrolled disease despite high-dose inhaled corticosteroids (ICS) and long-acting β2-adrenergic agonists (LABA).3 It often requires additional treatments, such as oral corticosteroids (OCSs), whose chronic use is responsible for several side-effects, including osteoporosis, diabetes, cataract, anxiety, and depression, increasing the already high SA-related economic burden.4 Type 2 inflammation, mediated by cytokines, such as interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), occurs in approximately 50% of asthmatic patients.5

SA treatment evolved over the past decade as several monoclonal antibody therapies have been licensed, such as targeting IgE (omalizumab), IL-5 (mepolizumab), and IL-5Rα (benralizumab).

Dupilumab is a fully human monoclonal antibody directed against the alpha subunit of the IL-4 receptor (IL-4Rα), blocking both IL-4 and IL-13 pathways,6 firstly designed for the treatment of moderate-to-severe atopic dermatitis (AD)7 and subsequently evaluated in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)8 and SA.9,10 Indeed, clinical trials9,10 showed that dupilumab is able to significantly reduce the rate of severe asthma exacerbations, to improve lung function and to reduce OCSs intake in patients with uncontrolled moderate-to-severe asthma.

Dupilumab was approved for the treatment of SA by the European Medicines Agency (EMA) in March 2019 and by the Italian Drug Agency (AIFA) in December 2020. Nevertheless, in September 2018, AIFA authorized the use of dupilumab according to the Named Patient Program (NPP) in patients with uncontrolled SA without further available treatment options.

In this retrospective, multicentre, real-life, observational study, we aimed to describe the clinical characteristics of patients involved in the NPP and the effectiveness of dupilumab in improving asthma exacerbations, pulmonary function, and Asthma Control Test (ACT), after 3, 6 and 12 months of treatment.

Materials and Methods

Study Design

We performed a multi-center, retrospective, observational study on all SA patients admitted to dupilumab NPP. Patients were enrolled in highly specialized outpatient facilities for the treatment of SA of 8 Italian hospitals [(1) A.O.U. Policlinico “G. Rodolico – San Marco”, Catania; (2) A.O.U. “Policlinico Giaccone”, Palermo; (3) Azienda Ospedale Università Padova, Padova; (4) A.O.U. “Arcispedale Sant’Anna”, Ferrara; (5) A.O.U. di Modena, Policlinico di Modena, Modena; (6) A.O.U. Policlinico di Bari “Giovanni XXIII”, Bari; (7) Azienda Ospedaliero Universitaria di Foggia, Foggia; (8) A.O.U. Ospedali Riuniti di Ancona, Ancona] between September 2018 and April 2019. This study followed the Declaration of Helsinki, met the standards of Good Clinical Practice (GCP), and was also approved by the Ethics Committee “Catania 1” at the Policlinico Hospital (Protocol Number 33/2020/PO – April 6th 2020). All patients signed a written informed consent.

Patient Population

Patients aged more than 18 years, with a diagnosis of SA according to the European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines1 and with confirmed adherence to maintenance therapy, based on both the assessment of how often the medications were refilled and correct inhalations technique, were included. To admit a patient into the NPP, physicians had to certify to the Italian Drug Agency (AIFA) and the local Ethics Committee that the patient had an uncontrolled SA and/or severe steroid side-effects, requiring an urgent step-up treatment without further therapeutical options. The authorization for treatment was given by the local Ethics Committees, AIFA and the drug manufacturer Sanofi. A blood eosinophil count ≥150 cells/μL or FeNO ≥ 25 ppb were not required since the prescribing criteria were not established at the time. Patients with a peripheral blood eosinophil count ≥ 1500 cells/μL in the previous year were excluded from the NPP in order to avoid cases of symptomatic hypereosinophilia.11 Dupilumab was administered every 2 weeks, starting with a loading dose of 600 mg and then maintaining doses of 300 mg.11

Data Collection and Assessment

Demographic [age, sex, body mass index (BMI)], asthma characteristics (age at onset, skin prick test to evaluate sensitization to common aeroallergens, maintenance therapies, previous anti-IgE and/or anti-IL-5 agents, total IgE count, asthma exacerbations in the previous year) and comorbidities [chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps, gastroesophageal reflux (GERD), atopic dermatitis] were collected at baseline. Number of exacerbations, pulmonary function tests, blood eosinophils count, fractional exhaled nitric oxide (FeNO), Asthma Control Test (ACT) score,12,13 and daily OCSs intake (prednisone mg/day) were assessed before starting the therapy with dupilumab and after 3, 6, and 12 months of treatment. Asthma exacerbations were defined as a disease worsening requiring ≥ 3 days of treatment with OCSs (or a double daily dose if already on OCSs).14 One patient had 2 exacerbations treated with cycles of corticosteroids < 7 days from each other and were considered as the same exacerbation. Lung function tests were performed according to ERS/ATS guidelines.15

Statistical Analysis

An established database was accessed for data analysis. Categorical variables are stated as number (n) and percentage (%). Normally distributed continuous variables are expressed as mean ± standard deviation (SD). Median and interquartile range (IQR) is used in the case of continuous nonparametric variables. Fisher exact or Chi-Square tests were used for comparisons of categorical variables. The normality of data distribution was checked using Kruskal–Wallis and Kolmogorov–Smirnov tests. Student t test, Mann–Whitney U-test, Dunnett’s multiple comparison test and Friedman test with Dunn’s post-hoc were used to compare variables, when appropriate. Statistical analysis and figures were generated using Prism version 9.0.0 (GraphPad Software Inc). A p-value < 0.05 (two-sided) was considered statistically significant.

Results

Patients’ Characteristics

Eighteen subjects were included in the NPP. Baseline patients’ characteristics are reported in Table 1. In particular, the mean age of the patients was 53.3±12.4 years and mean age at onset was 32.7±18.1 years; 12 out of 18 (12/18, 66.7%) patients were female. Over half of our patients (10/18, 55.6%) had positive skin prick tests; 15 patients (83.3%) had chronic rhinosinusitis, and 7 (38.9%) moderate-to-severe CRSwNP. All patients were treated with high-dose ICSs-LABAs; a long-acting muscarinic antagonist (LAMA) was added to this combination in 61.1% (11/18) of cases. Eleven patients (61.1%) were OCSs dependent [median dose 10 (5–25) mg/day]. Five patients (5/18, 27.8%) received a previous treatment with anti-IgE and/or anti-IL-5 agents, which were suspended for at least 4 months before starting dupilumab, due to the lack of response. During the 12 months prior to the anti-IL-4Rα treatment, the median annual exacerbation rate was 2 (0–3). In 7/18 (38.9%) the blood eosinophil count at baseline was <300cells/μL.

Table 1

Patients Baseline Demographic and Clinical Characteristics

	All (n=18)
Age, years, mean (SD)	53.3 (12.4)
Female, n (%)	12 (66.7)
BMI, mean (SD)	28.3 (4.2)
Age at onset, years, mean (SD)	32.7 (18.1)
Positive Skin Prick Test, n (%)	10 (55.6)
CRSwNP, n (%)	7 (38.9)
CRSsNP, n (%)	8 (44.4)
Atopic Dermatitis, n (%)	1 (5.6)
GERD, n (%)	5 (27.8)
High dose ICS-LABA, n (%)	18 (100)
LAMA, n (%)	11 (61.1)
Patients on OCS, n, (%)	11 (61.1)
OCS, mg/day, median (IQR)	10 (5–25)
Previous anti-IgE/anti IL-5 mAbs, n (%)	5 (27.8)
Asthma exacerbations/year, median (IQR)	2 (0–3)
ACT, mean (SD)	15.7 (5.1)
FEV1, %, mean (SD)	73.5 (19.5)
FEV1, L, mean (SD)	2.13 (1.1)
FeNO, ppb, median (IQR)	25 (20–80)
Patients with FeNO < 25 ppb	7 (38.9)
Eosinophil counts in peripheral blood, cells/μL median (IQR)	320 (190–532.5)
Patients with eosinophil counts in peripheral blood ≥ 300 cells/μL	11 (61.1)
Patients with eosinophil counts in peripheral blood ≥ 150 and <300 cells/μL	5 (27.8)
Patients with eosinophil counts in peripheral blood <150 cells/μL	2 (11.1)
IgE, UI/mL, mean (SD)	135 (57.4)

Notes: Normally distributed data are presented as mean and standard deviation (SD). Non-normally distributed variables are presented as median and interquartile range (IQR).

Abbreviations: BMI, body mass index; CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; GERD, gastroesophageal reflux disease; ICS-LABA, inhaled corticosteroids - long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; OCS, oral corticosteroids (prednisone); ACT, Asthma Control Test; FEV1, forced expiratory volume in the 1st second; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin-E.

Dupilumab Efficacy on Severe Asthma

The administration of dupilumab was able to improve all the evaluated outcomes after 12 months of treatment (Table 2). Asthma exacerbations significantly decreased from 2 (0–3) to 0 (0–1) (p=0.0068) (Figure 1A). Consequently, ACT score improved from mean 15.7±5.1 to 18.8±4.8 (p=0.023) after 3 months of treatment, reaching 22.4±1.7 (p<0.0001) at month 12 (Figure 1B). Sixteen patients (88.9%) achieved an ACT score equal to or greater than 20, a critical value indicative of a good overall asthma control. Furthermore, 66.7% of patients reported an ACT score increase ≥ 3 points (MCID)16 at the end of the follow-up. Pulmonary function also benefited from dupilumab add-on treatment, with a significant FEV1% improvement after 12 months (from 73.5±19.5% to 87.1±19.2%, p=0.0407) (Figure 1C). All 11 patients on OCSs were able to discontinue the steroid treatment (p<0.0001) with a significative daily-dose reduction after 3 months [from 10 (5–25) mg/day to 0 (0–5) mg/day, p=0.0333] (Figure 2A and B). FeNO also decreased from a median value of 25 (20–80) ppb to 21 (10.9–55.3) ppb (p=0.0190) after 3 months and to 14 (10–20) ppb after 12 (Figure 2C).

Table 2

Outcomes After 3 and 12 Months of Treatment

Total n=18	Baseline (B)	3 Months (3m)	B vs 3 m p-value	12 Months (12 m)	B vs 12 m p-value
Asthma exacerbations/year, median (IQR)	2 (0–3)	/	/	0 (0–1)	0.0068
ACT, mean (SD)	15.7 (5.1)	18.8 (4.8)	0.0230	22.4 (1.7)	<0.0001
ACT MCID, n, (%)	/	/	/	12 (66.7)	/
ACT ≥ 20, n, (%)	/	/	/	16 (88.9)	/
FEV1, %, mean (SD)	73.5 (19.5)	77.0 (6.5)	0.3733	87.1 (19.2)	0.0407
Patients on OCS (n=11), n, (%)	11 (100)	7 (63.64)	0.0902	0 (0)	<0.0001
OCS, mg/die, median (IQR)	10 (5–25)	0 (0–5)	0.0333	0.0 (0.0–0.0)	<0.0001
Eosinophil counts in peripheral blood, cells/μL median (IQR)	320 (190–532.5)	205 (120–565)	0.3650	220 (106–397.5)	0.0038
FeNO, ppb, median (IQR)	25 (20–80)	21 (10.9–55.3)	0.0190	14 (10–20)	0.0066

Notes: Normally distributed data are presented as mean and standard deviation (SD). Non-normally distributed variables are presented as median and interquartile range (IQR). Bold entries highlight statistically significant differences between Baseline (B) vs 3 months (3 m) and Baseline (B) vs 12 months (12 m) of treatment.

Abbreviations: ACT, Asthma Control Test; MCID, minimal clinically important difference; FEV1, forced expiratory volume in the 1st second; OCS, oral corticosteroids (prednisone); FeNO, fractional exhaled nitric oxide.

Figure 1

Effects of dupilumab on exacerbations (A), ACT score (B), and FEV1% (C). Exacerbations are expressed as median and interquartile range (IQR). ACT and FEV1 values are expressed as mean and standard deviation (SD). *p<0.05; **p<0.01; ****p<0.0001.

Figure 2

Effects of dupilumab on rate of patients on OCSs (A), OCSs dose (B) and FeNO values (C). The rate of patients on OCSs is expressed as a percentage (%) from the total. OCSs dose and FeNO values are expressed as median values and interquartile range (IQR). *p<0.05; **p<0.01; ****p<0.0001.

Blood Eosinophil Count During Treatment

The median blood eosinophil count progressively reduced during the treatment from 320 (190–532.5) cells/μL at baseline to 225 (106.3–397.5) cells/μL (p<0.0038) after 12 months of treatment (Figure 3). Nevertheless, we observed an increase of this value from baseline in 5 patients (27.8%) after 3 months, in 4 (22.2%) patients after 6 months, and in 2 (11.1%) patients after 12 months. In only two patients the threshold of 1000 cells/μL was exceeded (at month 3); in one case, the blood eosinophil count reached 3000 cells/μL starting from a baseline count of 1410 cells/μL.

Figure 3

Peripheral blood eosinophils over the 12 months of dupilumab. Each line with dots represents a patient eosinophil count at each follow-up visit. **p<0.01.

Vasculitis and allergic bronchopulmonary aspergillosis were excluded, the latter since no patients had a positive prick test for Aspergillus, total IgE count > 1000 IU/mL and related symptoms (dyspnea, fever and asthma worsening).17 As such, these hypereosinophilic cases were considered asymptomatic without affecting the efficacy of dupilumab.

Response According to Blood Eosinophil Count and FeNO Values at Baseline

To evaluate the clinical response according to the baseline blood eosinophil count, we compared patients with < 300 cells/μL (7 patients) vs ≥ 300 cells/μL (11 patients). As shown in Table 3, ACT score (21±4.42 vs 23±0.9, p=0.4791), FEV1 (93.2±22.7% vs 83.8±17.5%, p=0.4010) and OCSs use (no patients on OCSs after 12 months) were comparable in both groups after 12 months. Similarly, patients with a FeNO value < 25 ppb (7 patients) or ≥ 25 ppb (11 patients) showed no statistically significant differences at the end of the follow-up.

Table 3

Treatment Response According to Baseline Blood Eosinophil Count (< 300 Cells/μL vs ≥ 300 Cells/μL) and FeNO (< 25 ppb vs ≥ 25 ppb)

	Baseline			12 Months
Eos < 300 cells/μL, n=7; Eos ≥ 300 cells/μL, n= 11	Eos < 300 cells/μL	Eos ≥ 300 cells/μL	p-value	Eos < 300 cells/μL	Eos ≥ 300 cells/μL	p-value
ACT, mean (SD)	14.5 (4.5)	16.91 (5.22)	0.5019	23 (0.9)	21 (4.42)	0.4791
ACT MCID, n, (%)	/	/	/	7 (100)	10 (90.9)	0.9999
ACT ≥ 20, n, (%)	/	/	/	7 (100)	10 (90.9)	0.9999
FEV1, %, mean (SD)	75.6 (8.6)	72.5 (23.6)	0.7170	93.2 (22.7)	83.8 (17.5)	0.4010
Patients on OCS (n=11), n, (%)	5 (71.4)	6 (54.5)	0.6371	0 (0)	0 (0)	0.9999
OCS, mg/die, median (IQR)	7.5 (5–20)	10 (5–25)	0.6756	0 (0.0–0.0)	0 (0.0–0.0)	0.9999
	Baseline			12 Months
FeNO < 25 ppb, n=7; FeNO ≥ 25 ppb, n= 11	FeNO < 25 ppb	FeNO ≥ 25 ppb	p-value	FeNO < 25 ppb	FeNO ≥ 25 ppb	p-value
ACT, mean (SD)	14.1 (4.85)	16.6 (5.3)	0.5709	22.4 (1.61)	21.2 (4.6)	0.6549
ACT MCID, n, (%)	/	/	/	7 (100)	10 (90.9)	0.9999
ACT ≥ 20, n, (%)	/	/	/	7 (100)	10 (90.9)	0.9999
FEV1, %, mean (SD)	64.5 (9.7)	76.8 (21.5)	0.6852	76.0 (2.3)	83.3 (34.2)	0.3721
Patients on OCS (n=11), n, (%)	4 (57.1)	7 (63.6)	0.9999	0 (0)	0 (0)	0.9999
OCS, mg/die, median (IQR)	10.0 (5–20)	12.5 (5–25)	0.4855	0 (0.0–0.0)	0 (0.0–0.0)	0.9999

Notes: Normally distributed data are presented as mean and standard deviation (SD). Non-normally distributed variables are presented as median and interquartile range (IQR).

Abbreviations: Eos, eosinophils; ACT, Asthma Control Test; MCID, minimal clinically important difference; FEV1, forced expiratory volume in the 1st second; OCS, oral corticosteroids (prednisone); FeNO, fractional exhaled nitric oxide.

Discussion

In this multi-center, retrospective, real-world study, the dupilumab add-on treatment was able to drastically reduce the number of exacerbations and the OCSs use, improving at the same time pre-bronchodilator FEV1% values and asthma control.

To the best of our knowledge, this is one of the first evidences18,19 of the real-life effectiveness of dupilumab in SA patients outside clinical trials.

Patients were included in the NPP after an evaluation of their clinical characteristics and SA phenotype by physicians. Indeed, 7/18 (38.9%) patients had a concomitant moderate-to-severe nasal polyposis, 1/18 (5.6%) patients had an atopic dermatitis, 5/18 (27.8%) patients were previously treated with anti-IgE omalizumab and/or anti-IL-5 mepolizumab and/or were included in anti-IL-5Rα benralizumab clinical trials, with an inadequate clinical response. Furthermore, in 8/18 (44.4%) cases the skin prick tests for any perennial aeroallergens were negative, and the peripheral blood count was ≥ 300 cells/μL in 11/18 (61.1%) cases.

Due to these values, the patients could not receive omalizumab20 or mepolizumab,21,22 the two SA monoclonal antibodies available in Italy at the time. Moreover, all these patients could not be included in dupilumab and/or benralizumab clinical trials since the enrollment was already completed or due to inclusion and exclusion criteria.

Similar to the Italian NPP, a nominative Authorization for Temporary Use (nATU) program for dupilumab early access was implemented in France in September 2017 (NCT04022447).18 Sixty-four SA patients who reached a therapeutic dead-end were enrolled in 13 French pulmonary medicine departments, regardless of their airway T2 inflammation status. Notwithstanding a high number of exacerbations (median 4 in the previous year), the OCSs consumption (mean dose 23.5 ± 15 mg/day) and a significantly impaired lung function (mean FEV1 59%), after one year of dupilumab add-on treatment, the number of exacerbations was reduced by 75%, about 24% of patients stopped the treatment with OCSs, 78% of them were able to reduce the daily dose ≥ 50% and the FEV1 improved by 10%. These results were comparable and, in some cases, superior to those obtained in clinical trials, regardless of the baseline value of eosinophilia (< or ≥ 150 cells/μL).

In our cohort of patients, we observed a reduction of asthma exacerbations in almost all cases in comparison to the year before, far superior to the results reported in Phase III QUEST (47.7%) and VENTURE (59%) trials9,10 and in French nATU study (75%).18 To this extent, ACT score significantly improved (approximately 3 points) after three months of treatment from baseline. Moreover, 88.9% of patients reached the critical threshold of 20, indicative of a good overall asthma control after 12 months.

It is known that the progressive loss of lung function is a trigger of asthma exacerbations, which are responsible for airway remodeling, nurturing a loop that characterizes the physiopathology of SA.23,24 We reported a significant statistical increase of pre-bronchodilator FEV1% mean value from 73.5% to 87.1% (absolute difference: 14%) at the end of the study, which contributed to reduce the number of asthma exacerbations and to improve symptoms.

Dupilumab add-on treatment was able to reduce OCSs intake by 71.9% in glucocorticoid dependent SA in the phase III VENTURE10 trial and the French nATU study showed a ≥ 50% reduction of the daily dose in 78% of patients.18 In our study, 36.33% of patients progressively reduced and suspended OCSs after 3 months of treatment with dupilumab, until a complete weaning of such a noxious treatment after 12 months. Even in this case, our real-world data proved to be superior to those obtained in the clinical trial,10 despite a comparable baseline daily intake [median 10 (5–25) in our study vs mean 11.75 ± 3.54 mg/day after adjustment].

Taken together, all the above-mentioned findings showed that dupilumab exerted very beneficial effects already after 3 months of treatments, with a continuous trend of improvements toward the 12 months.

Randomized controlled trials showed that baseline eosinophil counts ≥150 and ≥300 cells/μL were associated with better asthma outcomes. Italian NPP, likewise French nATU,18 was designed without established inclusion criteria in terms of baseline eosinophilic counts in peripheral blood and FeNO since the results of phase III trials9,10 were not fully unveiled. For this reason, patients with a FeNO value < 25 ppb and blood eosinophil count < 150 cells/μL were included. In our cohort, baseline blood eosinophils (< or ≥300 cells/μL) or FeNO (< or ≥25 ppb) did not affect ACT score, FEV1%, and OCSs intake, but it is necessary to remember that the sample size of these subgroups was limited (7 patients for FeNO < 25 ppb and baseline blood eosinophils <300 cells/μL vs 11 patients for FeNO ≥25 ppb and blood eosinophils ≥300 cells/μL).

An asymptomatic hypereosinophilia with ≥ 1000 cells/μL was observed in two cases. An increase in blood eosinophil count during treatment with dupilumab could be due to the reduction of Eotaxin-3 and specific adhesion molecules, leading to an inhibition of the recruitment of the cells into the tissues, without altering their release from bone marrow, which is strongly dependent on IL-5.25 As a result, dupilumab caused transient eosinophilia in five patients without any clinical manifestations. The treatment was generally well tolerated: no patients withdrew the drugs for adverse events.

Furthermore, dupilumab represents a valid therapeutic option for non-responders to other biological therapies. In fact, in the 5 patients (27.8%) switched from omalizumab and/or mepolizumab to dupilumab due to lack of a therapeutic response, an improvement of all clinical outcomes was observed. These data further confirm the results obtained by Mümmler et al19: 38 SA patients switched from anti-IgE and anti-IL-5 agents to dupilumab showed greater clinical benefits in terms of exacerbation, pulmonary function, OCSs intake, and asthma symptoms.

Conclusion

In conclusion, our analysis of NPP data confirm the effectiveness of dupilumab in improving asthma outcomes in the real-life setting and transient hypereosinophilia did not modify treatment response. Although we carefully evaluated all the Italian NPP patients, this study has some limitations related to the small population involved and uncontrolled retrospective design leading to underpowered statistical analysis and reduced generalizability of the results. Indeed, larger SA cohorts treated with dupilumab in real-life settings are necessary to confirm our findings.